Context Therapeutics (CNTX) investor relations material

Executive summary

• Clinical-stage biopharma advancing TCE bispecific antibodies for solid tumors, with CTIM-76, CT-95, and CT-202 as lead candidates.

• CTIM-76 received FDA Fast Track designation for platinum-resistant ovarian cancer; interim Phase 1a data expected June 2026.

• CT-95 interim Phase 1a data expected September 2026; CT-202 Phase 1 initiation planned for Q3 2026 after regulatory approval in Australia.

• Cash and cash equivalents of $54.5 million as of March 31, 2026, expected to fund operations into mid-2027.

• Net loss for Q1 2026 was $8.7 million, with an accumulated deficit of $139.6 million as of March 31, 2026.

Financial highlights

• Cash and cash equivalents totaled $54.5 million at March 31, 2026, down from $66.0 million at year-end 2025.

• Research and development expenses rose to $7.0 million in Q1 2026, up 103% year-over-year, driven by pipeline advancement and personnel costs.

• General and administrative expenses increased to $2.3 million in Q1 2026, mainly due to higher personnel and professional fees.

• Net loss increased 90% year-over-year to $8.7 million, or $(0.09) per share.

• Cash used in operating activities was $11.4 million for Q1 2026, compared to $5.0 million in Q1 2025.

Outlook and guidance

• Cash runway expected to fund operations into mid-2027, covering Phase 1a trials for CTIM-76 and CT-95 and initiation of CT-202 trial.

• Additional capital will be required to support ongoing and future development and commercialization efforts.